SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Remon, Jordi (HM Hospitales)
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Diz Taín, Pilar (Hospital Universitario de León)
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia)
González-Larriba, J.L. (Hospital Universitario Clínico San Carlos (Madrid))
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo))
Mielgo-Rubio, X. (Hospital Universitario Fundación Alcorcón)
Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló)
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau)
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià))
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Chemotherapy ; Lenvatinib ; Multidisciplinary ; Nivolumab ; Thymic epithelial tumours
Published in:	Clinical & Translational Oncology, Vol. 24 Núm. 4 (april 2022) , p. 635-645, ISSN 1699-3055

DOI: 10.1007/s12094-022-02788-w
PMID: 35122634

11 p, 808.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles